

# A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

NCT07275736

---

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Juventas Cell Therapy Ltd.
Enrollment	18 participants

## Key Eligibility Criteria

---

### Inclusion (35)

- Patients who are willing to sign the informed consent form;
- Aged 18-75 years, male or female;
- At screening, subjects with relapsed/refractory antibody-mediated inflammatory neurological diseases without effective treatment, the expression of CD19+ B cells in peripheral blood and meeting the special criteria for different indications include:
- Neuromyelitis optica spectrum disorder (NMOSD): Comply with the diagnostic criteria for NMOSD of the International panel for NMO diagnosis (IPND) in 2015 and meet the following requirements:
- aquaporin 4 (AQP4) -IgG positive
- ... and 30 more (see full listing online)

### Exclusion (22)

- Current medical conditions or neurological disorders that may affect the effectiveness assessment, such as dementia, schizophrenia, bipolar disorder, major depressive disorder, history of multiple traumatic brain injury, current alcohol/drug abuse or dependence, or alcohol/drug dependence within the past two years.
- Pregnancy or breastfeeding;
- Have received organ or hematopoietic stem cell transplantation in the past;
- There has been a history of new thrombosis or organ infarction within the past six months;
- Patients diagnosed with active connective tissue diseases and requiring non-hormonal immunosuppressants/modulators for treatment;
- ... and 17 more (see full listing online)

## Locations (1 total)

---

Beijing Tiantan Hospital, Beijing, China